Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib in B-Cell Malignancies
NCT04014205Phase 2Active, not recruiting
- Sponsor
- InnoCare Pharma
- Start
- Nov 2019
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of orelabrutinib in B-cell malignancy, sponsored by InnoCare Pharma. Started Nov 2019; status: active, not recruiting.
02
Drugs
orelabrutinib
03
Conditions
B-cell malignancy
Beyond the preview
Go deeper on NCT04014205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04014205.